Biodesix Q2 revenue rises 34% to $26.9 million; net loss narrows to $7.3 million
Biodesix reported second quarter 2026 results on August 5, 2026, with total revenue of $26.9 million, up 34% from the prior year, and a net loss of $7.3 million, down 37% from $11.5 million. The company kept its full-year 2026 revenue guidance of $108-114 million, which the filing says implies about 25% growth at the midpoint, so shareholders see both faster sales and a smaller loss with the outlook unchanged.
Key points
- Diagnostic Testing revenue rose 42% to $25.4 million on a 38% increase in test volumes to 20,900
- Development Services revenue fell to $1.5 million from $2.1 million, which the company attributed to timing of project completion and revenue recognition
- Gross margin was 82%, up 200 basis points; Adjusted EBITDA loss narrowed to $3.2 million from $7.2 million
- FY 2026 revenue guidance of $108-114 million was maintained
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.